Researchers have discovered that a subset of clear cell ovarian cancers, traditionally resistant to chemotherapy and immunotherapy, can respond to immune checkpoint inhibitors. The findings, published in a peer-reviewed journal, are based on studies in both human patients and mouse models.
The team identified a specific molecular signature that predicts response to immunotherapy, potentially enabling doctors to select patients who would benefit most. In the study, tumors with this signature showed significant shrinkage when treated with PD-1/PD-L1 inhibitors.
Clear cell ovarian cancer accounts for about 5-10% of all ovarian cancers and is known for its poor prognosis and resistance to standard treatments. This breakthrough offers a new therapeutic avenue for patients who currently have limited options.
Further clinical trials are planned to confirm these findings and to develop a companion diagnostic test. The researchers emphasize that while the results are promising, more research is needed before the treatment becomes standard practice.
